A FACTORIAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF THE CO-ADMINISTRATION OF MK-0431 AND METFORMIN IN PATIENTS WITH DIABETES MELLITUS TYPE 2 WHO HAVE AN INAPPROPRIATE GLYCEMIC CONTRO

MERCK & CO.INC.,0 个研究点目标入组 0 人开始时间: 2005年5月27日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•a) The patient suffers from diabetes mellitus type 2 (T2DM).
•b) The patient is between> 18 and <78 years of age.
•c) The patient understands the study procedures and agrees to participate in it.
•d) The patient is not pregnant or nursing or plans to become pregnant during the entire study and the post-study follow-up period.
•e) The patient is a man, or a woman with very few chances of conceiving.
•f) The patient meets one of the following criteria: 1) The patient currently does not receive an antihyperglycemic agent and has an HbAic level> 7.5% and <11% at Visit 1 / Screening Visit. 2) The patient is not currently receiving any antihyperglycemic agent and has an HbAic level> 11% in Visit 1 / Screening Visit. 3) The patient is currently receiving monotherapy with an antihyperglycemic agent or dual combination oral therapy and has a HbAic level> 7% and <10.5% in Visit 1 / Screening Visit. 4) The patient is currently receiving monotherapy or dual combination oral therapy, has an HbAic level> 6.5% and <7% at Visit 1 / Screening Visit, and has been approved by the Merck clinical monitor.

•a) The patient has developed a medical condition or disorder that, in the opinion of the researcher or Merck´s clinical monitor, could put the patient at risk.
•b) The patient is receiving or is likely to require an excluded or prohibited medication.

发起方

MERCK & CO.INC.,